Amounts of Tyrosine Kinase Inhibitors Used in Hospitals in Nanjing from 2017 to 2019

doi:10.19803/j.1672-8629.2021.08.09

Abstract

Abstract: Objective To analyze the changes of usage of tyrosine kinase inhibitors in hospitals in Nanjing between 2017 and 2019. Methods The types, volume of sales, defined daily dose system (DDDs), and defined daily dose cost (DDDc) of tyrosine kinase inhibitors in 36 hospitals in Nanjing between 2017 and 2019 were analyzed statistically. Results The sales volume and DDDs of tyrosine kinase inhibitors in 36 hospitals in Nanjing increased at an average annual rate of 102.42% and 111.64% respectively between 2017 and 2019. Gefitinib remained among the top three in terms of sales amount and DDDs for three consecutive years. Osimertinib and anlotinib showed the fastest growth in sales amount and DDDs. Most of the tyrosine kinase inhibitor drugs trended up in DDDs except imatinib, the DDDs value of which decreased year by year. In addition, the sales amount and order ratio of dasatinib and nilotinib decreased simultaneously. Conclusion Tyrosine kinase inhibitors are widely used in hospitals in Nanjing, with a rapid growth rate in consumption and sales amount despite the decline in the DDDc of most of the drugs．

Key words: tyrosine kinase inhibitor, sales amount, DDDs, DDDc, drug utilization

CLC Number:

R979.1 R73

LI Youjia, XIE Jiao, JI Cheng, YAO Hongyi. Amounts of Tyrosine Kinase Inhibitors Used in Hospitals in Nanjing from 2017 to 2019[J]. Chinese Journal of Pharmacovigilance, 2021, 18(8): 743-747.

References

[1] Zheng RS, Sun KX, Zhang SW, et al.Report of cancer epidemiology in China, 2015[J]. Chin J Oncol(中华肿瘤杂志), 2019, 41(1): 19-28.
[2] Chen W, Zheng R, Baade PD, et al.Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2): 115-132.
[3] Liang YH, Huang L, Liu HG.Analysis of 618 cases reports of antitumor drug adverse reactions[J]. Northwest Pharm J(西北药学杂志), 2017, 32(5): 670-673.
[4] National Health Commission of the People's Republic of China. Guidelines for the clinical application of new anti-tumor drugs, 2019[J]. J Multidiscip Cancer Manage (Electronic Version)(肿瘤综合治疗电子杂志), 2020, 6(1): 16-47.
[5] Zhang XX, Sun LQ, Zang J.Research progress of small molecule tyrosine kinase inhibitors as antitumor agents[J]. Chin J New Drug(中国新药杂志), 2018, 27(22): 2616-2629.
[6] Chen XQ, Jin YY, Tang G.Pharmacology(新编药物学)[M]. 18th ed. Beijing: People's Medical Publishing House, 2018: 851-929.
[7] Ji C, Li J.Utilization trend of albumin and immunoglobulin biolo-gical products in hospitals of nanjing during 2016-2018[J]. Chin J Pharmacoepidem(药物流行病学杂志), 2020, 29(7): 484-487.
[8] Chang QQ, Peng Y, Wang GJ, et al.Clinical research progress of small molecule tyrosine kinase inhibitors as anti-hepatocellular carcinoma agents[J]. Chin J Clin Pharm Th(中国临床药理学与治疗学), 2019, 24(8): 948-956.
[9] Choi YJ, Park GM, Rho JK, et al.Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors[J]. PLoS One, 2013, 8(12): e81393.
[10] Fang WT, Luo C, Dai HZ, et al.Application analysis and medicare payments prediction of new selected anti-tumor drugs of medical insurance in Nanjing city[J]. Chin J Hosp Pharm(中国医院药学杂志), 2018, 38(11): 1131-1137.
[11] Liu ZH, Luo MH, Zou AM, et al.Clinical observation of molecular targeted therapy with gefitinib for advanced lung adenocarcinoma[J]. Chin J Mod Drug Appl(中国现代药物应用), 2020, 14(21): 121-122.
[12] Ettinger DS, Wood DE, Aggarwal C, et al.NCCN guidelines insights: non-small cell lung cancer, version 1. 2020[J]. J Natl Compr Canc Netw, 2019, 17(12): 1464-1472.
[13] Huang Y, Zhang L.Interpretation of the updated key points of the CSCO non-small cell lung cancer diagnosis and treatment guidelines, 2020[J]. J Clin Internal Med(临床内科杂志), 2020, 37(8): 603-605.
[14] Wang J, Zhao Y, Wang Q, et al.Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third or further-line treatment[J]. Cancer Biol Med, 2018, 15(4): 443-451.
[15] Chinese Association for Clinical Oncologists, Expert Committee of Vascular Targeted Therapy of Chinese Society of Clinical Oncology, Cancer Targeted Therapy Professional Committee of China Anti-Cancer Association. Chinese expert consensus on anlotinib hydrochloride for advanced lung cancer (2020 edition)[J]. Chin J Onclo(中华肿瘤杂志), 2020, 42(10): 807-816.
[16] Yan GT, Hu JP, Zhang YT, et al.Market analysis of imatinib mesylate[J]. Coal Chem Ind(煤炭与化工), 2013, 36(6): 44-45, 74.
[17] Cao HZ, Sun H, Sun YX, et al.Research progress in the correlation between miRNA and imatinib resistance[J]. Chinese Bulletin of Life Sciences(生命科学), 2020, 36(6): 581-589.